ORCHARD THERAPEUTICS

Company snapshot

Orchard Therapeutics (Netherlands) is a pharma organization headquartered in EU. Primary therapeutic focus areas include Metachromatic Leukodystrophy (MLD), Mucopolysaccharidosis type I, Hurler Syndrome, Mucopolysaccharidosis type I Hurler. NovaPharmaNews links 5 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (3), phase 2 (2).

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ORCHARD THERAPEUTICS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for ORCHARD THERAPEUTICS.

1. Jun 8, 2026 Clinical update

   OTL-203-02 — Phase 3

2. Jun 8, 2026 Clinical update

   TigetT10_MPSIH — Phase 2

3. Jun 8, 2026 Clinical update

   Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion — Phase 3

4. Jun 8, 2026 Clinical update

   Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion — Phase 3

5. Jun 8, 2026 Clinical update

   Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion — Phase 2

View all clinical trial activity →

• What is ORCHARD THERAPEUTICS?

  Orchard Therapeutics (Netherlands) is a pharma organization headquartered in EU. Primary therapeutic focus areas include Metachromatic Leukodystrophy (MLD), Mucopolysaccharidosis type I, Hurler Syndrome, Mucopolysaccharidosis type I Hurler. NovaPharmaNews links 5 clinical program

• Is ORCHARD THERAPEUTICS publicly traded?

  ORCHARD THERAPEUTICS appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does ORCHARD THERAPEUTICS develop or market?

  We link 12 drug profile(s) where ORCHARD THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/orchard-therapeutics-netherlands-b-v#company-drugs.

• What are the latest developments for ORCHARD THERAPEUTICS?

  In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ORCHARD THERAPEUTICS focus on?

  ORCHARD THERAPEUTICS focuses on Metachromatic Leukodystrophy (MLD), Mucopolysaccharidosis type I, Hurler Syndrome, Mucopolysaccharidosis type I Hurler based on our analysis of their pipeline programs and drug development activities.